AP543A - Process for the preparation of azamacrocyclic or acyclic aminophosphonate ester derivatives. - Google Patents
Process for the preparation of azamacrocyclic or acyclic aminophosphonate ester derivatives. Download PDFInfo
- Publication number
- AP543A AP543A APAP/P/1994/000639A AP9400639A AP543A AP 543 A AP543 A AP 543A AP 9400639 A AP9400639 A AP 9400639A AP 543 A AP543 A AP 543A
- Authority
- AP
- ARIPO
- Prior art keywords
- formula
- phosphite
- paraformaldehyde
- thf
- comprises reacting
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 66
- -1 acyclic aminophosphonate ester Chemical class 0.000 title claims abstract description 22
- 238000002360 preparation method Methods 0.000 title description 19
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 40
- 229910052757 nitrogen Inorganic materials 0.000 claims description 23
- 229930040373 Paraformaldehyde Natural products 0.000 claims description 22
- 229920002866 paraformaldehyde Polymers 0.000 claims description 22
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 claims description 21
- 239000003446 ligand Substances 0.000 claims description 18
- 239000007983 Tris buffer Substances 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 claims description 14
- 230000007062 hydrolysis Effects 0.000 claims description 13
- 238000006460 hydrolysis reaction Methods 0.000 claims description 13
- XTTGYFREQJCEML-UHFFFAOYSA-N tributyl phosphite Chemical compound CCCCOP(OCCCC)OCCCC XTTGYFREQJCEML-UHFFFAOYSA-N 0.000 claims description 13
- 125000000217 alkyl group Chemical group 0.000 claims description 12
- BDZBKCUKTQZUTL-UHFFFAOYSA-N triethyl phosphite Chemical compound CCOP(OCC)OCC BDZBKCUKTQZUTL-UHFFFAOYSA-N 0.000 claims description 12
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 claims description 11
- 238000006243 chemical reaction Methods 0.000 claims description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims description 10
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 9
- 239000002253 acid Substances 0.000 claims description 9
- 239000002585 base Substances 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 8
- 229910052700 potassium Inorganic materials 0.000 claims description 7
- 239000006184 cosolvent Substances 0.000 claims description 6
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims description 6
- 229910052708 sodium Inorganic materials 0.000 claims description 6
- QOPBTFMUVTXWFF-UHFFFAOYSA-N tripropyl phosphite Chemical compound CCCOP(OCCC)OCCC QOPBTFMUVTXWFF-UHFFFAOYSA-N 0.000 claims description 6
- 229940120146 EDTMP Drugs 0.000 claims description 5
- NFDRPXJGHKJRLJ-UHFFFAOYSA-N edtmp Chemical compound OP(O)(=O)CN(CP(O)(O)=O)CCN(CP(O)(O)=O)CP(O)(O)=O NFDRPXJGHKJRLJ-UHFFFAOYSA-N 0.000 claims description 5
- QBPPRVHXOZRESW-UHFFFAOYSA-N 1,4,7,10-tetraazacyclododecane Chemical compound C1CNCCNCCNCCN1 QBPPRVHXOZRESW-UHFFFAOYSA-N 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 238000005903 acid hydrolysis reaction Methods 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- RPNUMPOLZDHAAY-UHFFFAOYSA-N Diethylenetriamine Chemical compound NCCNCCN RPNUMPOLZDHAAY-UHFFFAOYSA-N 0.000 claims description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 3
- CYTQBVOFDCPGCX-UHFFFAOYSA-N trimethyl phosphite Chemical compound COP(OC)OC CYTQBVOFDCPGCX-UHFFFAOYSA-N 0.000 claims description 3
- 150000008044 alkali metal hydroxides Chemical class 0.000 claims description 2
- 150000001923 cyclic compounds Chemical class 0.000 claims description 2
- 150000003009 phosphonic acids Chemical class 0.000 claims description 2
- 239000002798 polar solvent Substances 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims 2
- VPGQJHBMALMMJQ-UHFFFAOYSA-N 1-(pyridin-2-ylmethyl)-1,4,7,10-tetrazacyclododecane Chemical compound C=1C=CC=NC=1CN1CCNCCNCCNCC1 VPGQJHBMALMMJQ-UHFFFAOYSA-N 0.000 claims 1
- BNVVMEAPZVKHHC-UHFFFAOYSA-N P1(OCCCCCCCCCO1)=O Chemical compound P1(OCCCCCCCCCO1)=O BNVVMEAPZVKHHC-UHFFFAOYSA-N 0.000 claims 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
- 229940090960 diethylenetriamine pentamethylene phosphonic acid Drugs 0.000 claims 1
- DUYCTCQXNHFCSJ-UHFFFAOYSA-N dtpmp Chemical compound OP(=O)(O)CN(CP(O)(O)=O)CCN(CP(O)(=O)O)CCN(CP(O)(O)=O)CP(O)(O)=O DUYCTCQXNHFCSJ-UHFFFAOYSA-N 0.000 claims 1
- 239000011591 potassium Substances 0.000 claims 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 1
- 150000002148 esters Chemical class 0.000 description 25
- 238000005481 NMR spectroscopy Methods 0.000 description 20
- 150000001875 compounds Chemical class 0.000 description 16
- 239000007787 solid Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 8
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- 238000001228 spectrum Methods 0.000 description 6
- 150000001412 amines Chemical class 0.000 description 5
- 238000004679 31P NMR spectroscopy Methods 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- RCXMQNIDOFXYDO-UHFFFAOYSA-N [4,7,10-tris(phosphonomethyl)-1,4,7,10-tetrazacyclododec-1-yl]methylphosphonic acid Chemical compound OP(O)(=O)CN1CCN(CP(O)(O)=O)CCN(CP(O)(O)=O)CCN(CP(O)(O)=O)CC1 RCXMQNIDOFXYDO-UHFFFAOYSA-N 0.000 description 3
- 125000002015 acyclic group Chemical group 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000000032 diagnostic agent Substances 0.000 description 3
- 229940039227 diagnostic agent Drugs 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000000607 proton-decoupled 31P nuclear magnetic resonance spectroscopy Methods 0.000 description 3
- VILCJCGEZXAXTO-UHFFFAOYSA-N 2,2,2-tetramine Chemical compound NCCNCCNCCN VILCJCGEZXAXTO-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000002518 distortionless enhancement with polarization transfer Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 150000002829 nitrogen Chemical group 0.000 description 2
- PTMHPRAIXMAOOB-UHFFFAOYSA-N phosphoramidic acid Chemical compound NP(O)(O)=O PTMHPRAIXMAOOB-UHFFFAOYSA-N 0.000 description 2
- 150000003141 primary amines Chemical class 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 150000003335 secondary amines Chemical class 0.000 description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
- 238000004009 13C{1H}-NMR spectroscopy Methods 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- 125000006479 2-pyridyl methyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 1
- 229910052688 Gadolinium Inorganic materials 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229910018828 PO3H2 Inorganic materials 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical class OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- GATNOFPXSDHULC-UHFFFAOYSA-N ethylphosphonic acid Chemical compound CCP(O)(O)=O GATNOFPXSDHULC-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000001208 nuclear magnetic resonance pulse sequence Methods 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- AQSJGOWTSHOLKH-UHFFFAOYSA-N phosphite(3-) Chemical class [O-]P([O-])[O-] AQSJGOWTSHOLKH-UHFFFAOYSA-N 0.000 description 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 1
- 238000000079 presaturation Methods 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- KZUNJOHGWZRPMI-AKLPVKDBSA-N samarium-153 Chemical compound [153Sm] KZUNJOHGWZRPMI-AKLPVKDBSA-N 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6524—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having four or more nitrogen atoms as the only ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A novel process for the preparatin of azamacrocyclic or acyclic aminophosphonate ester derivatives
Description
PROCESS FOR THE PREPARATION OF AZAMACROCYCLIC OR ACYCLIC AMINOPHOSPHONATE ESTER DERIVATIVES
This invention concerns a novel process for the preparation of azamacrocydic or acyclic aminophosphonate ester derivatives. Such process provides ligands which are useful as diagnostic or therapeutic agents.
Macrocydic aminophosphate esters are receiving considerable attention as diagnostic and therapeutic agents. The general synthetic methodology for preparing chelating agents of this type utilizes an amine in combination with phosphorous acid, formaldehyde and hydrochloric acid to provide the aminophosphonic acid, e.g. 1,4,7,10-tetraazacyclododecane10 1,4,7,10-tetramethylenephosphonic acid (DOTMP). Alternatively, methylenephosphonate functionality can be introduced by substituting a di- or tri-alkyl phosphite in the place of phosphorous acid in the prior procedure, to generate the corresponding dialkylphosphonate ester. These esters can be hydrolyzed under basic conditions to give the monoalkylphosphonate half esters. In addition, these full esters can be hydrolyzed under acidic conditions to give phosphomc acids, e g. DOTMP (see published application WO 91/07911). The general synthetic approach to aminophosphonates using either di- or tri-alkyl phosphites is documented in the literature by the reaction of various linear amines and using standardized procedures.
The present invention is directed to a process for preparing azamacrocydic or acyclic aminophosphonate ester derivatives which possess at least one secondary or primary nitrogen atom substituted with at least one moiety of the formula
-CH2PO3RR1 (I) wherein:
R is H or C1-C5 alkyl; with the proviso that each R is the same group;
R1 is C1-C5 alkyl, H, Na or K; with the proviso that each R and R1 is the same group when C1-C5 alkyl;
which comprises reacting the corresponding unsubstituted amine compound with a trialkyl phosphite and paraformaldehyde to provide the derivatives of Formula (I) wherein all R and R1 equal C1-C5 alkyl; and
3Q (a) optionally followed by aqueous base hydrolysis to provide the derivatives of
Formula (I) wherein R is C1-C5 alkyl and R1 is H, Na or K; and/or (b) optionally followed by acid hydrolysis to provide the derivatives of Formula (I) wherein all R and R1 equal H.
When the above ligands of Formula (I) have:
(i) all R and R1 equal H, the ligands are referred to as phosphonic acids;
(ii) all R equal H, and all R1 equal C1-C5 alkyl, the ligands are referred to herein as phosphonate half esters; and
AP/P/ 9 4 / 0 0 6 3 9
-lbBAD ORIGINAL ft
41,184-ίI.
(iii) all R and R1 equal C1-C5 alkyl, the ligands are referred to as phosphorate esters.
In some of our copending applications and patents we have discussed the use of these azamacrocydic or acyclic aminophosphonate ester derivatives of Formula (I) as diagnostic agents. Particularly, the half esters are useful as tissue specific magnetic resonance imaging (MRI) contrast agents when chelated with gadolinium. Several azamacrocydic or acyclic aminophosphonic acids, e g. DOTMP or EDTMP, when chelated with samarium-153 are useful as pain relief agents for calcific tumors in cancer patients.
The compounds of Formula (I) which are azamacrocydic or acyclic
IQ aminophosphonate ester derivatives which possess at least one secondary or primary nitrogen atom substituted with at least one moiety of the formula
-ch2po3rri (I) wherein:
R is H or C1-C5 alkyl; with the proviso that each R is the same group;
15 R1 is C1-C5 alkyl, H, Na or K; with the proviso that each R and R1 is the same group whenC,-Cs alkyl;
encompass known ligands and also those claimed in our copending applications.
The ligands used as starting materials to make the compounds of Formula (I) are known in the art. Some examples of these acyclic amine ligands are
2Q ethylenediamine (EDA);
diethylenetriamine (DTA); triethylenetetraamine (TTA); and numerous known linear or branch chain primary or secondary amines.
Some examples of azamacrocydic amine ligands are
2s 1,4,7,10-tetraazacydododecane (Cyden); and other known secondary azamacrocydic amines.
The azamacrocydic or acyclic aminophosphonate derivatives encompassed with a moiety of Formula (I) must have at least one secondary or primary nitrogen which is substituted with the moiety of Formula (I). Preferably, the number of nitrogen atoms present which may
3Q be substituted by a moiety of Formula (I) is from 2 to 10, preferably from 2 to 6. Usually the nitrogen atoms are separated from each other by at least two carbon atoms. Thus these derivatives can be represented by the formula
A-(N-CH2CH2-N)q-Z (II) wherein:
q is an integer from 1 to 5 inclusive;
A may be 0, 1 or 2 moieties of Formula (I) or hydrogen;
Z may be 0, 1 or 2 moieties of Formula (I) or hydrogen;
with the proviso that at least one A or Z moiety of Formula (I) is present; and
AP/P/ 9 4 / 0 0 6 39
41,184-Γ
ΑΡ. Ο Ο 5 4 3
A and Ζ may be joined to form a cyclic compound.
Examples of suitable azamacrocyclic amine ligands that are discussed in our copending applications are shown by the following formula:
The terms used in Formula (I) and for this invention are further defined as follows. C1-C5 alkyl”, include both straight and branched chain alkyl groups. Trialkyl phosphite*
2$ includes any alkyl'which in the resulting product of Formula (I) has desirable water solubility following hydrolysis, e.g. tri(C-| -Ci 0 alkyl) phosphite, preferably tri (Ci -C4 alkyl) phosphite, including both straight and branched chain alkyl groups.
When the azamacrocyclic ligands of Formula (I) wherein the full esters (R and R1 are both the same C1-C5 alkyl) are prepared, pressure is not critical so that ambient pressure is used. As the reaction is exothermic, the temperature is controlled to be maintained below 40°C during the first hour; and after the first hour, the temperature can be raised to facilitate completion of the reaction but need not exceed about 90°C. The pH of the reaction is not critical and the reaction is non-aqueous. The reaction is run in the presence of a non-aqueous liquid, such as the trialkyl phosphite reagent or a solvent. A solvent is preferably used;
examples of such solvents are: aprotic polar solvents such as tetrahyrdofuran (THF), dioxane, acetonitrile, and other similar inert, non-aqueous solvents; alcohols where the alkyl portion is the same as the R obtained, such as methanol, ethanol and propanol. THF is the preferred
2 9 0 0 / 9 5 /d/dV
184-F solvent. The order of addition of the reactants and the azamacrocydic or acyclic aminophosphonate starting material is not critical.
When the acyclic ligands of Formula (I) wherein the full esters (R and R1 are both the same C1-C5 alkyl) are prepared, the reaction is significantly more exothermic. It is critical to control the temperature below 40°C for the first hour of the reaction. Methods to effectively control the temperature are known, such as the presence of an ice bath, dilution with solvents or the order and/or speed of addition of reagents. For example, one method involves combining the trialkyl phosphite and paraformaldehyde and initially cooling the mixture, followed by the controlled addition of the acyclic amine, while maintaining the temperature
IQ by using an ice bath.
All the ligands of Formula (I) wherein the half esters are prepared (R = C1-C5 alkyl and R1 = H, Na or K) by aqueous base hydrolysis is accomplished after the formation of the corresponding full ester. Examples of suitable bases are alkali metal hydroxides, eg. sodium or potassium hydroxide. The amount of base used is from about 1-10 equivalents per secondary amine or 2-20 equivalents per primary amine. As the alkyl chain length of the R or R1 group is propyl or higher, then a cosolvent is used with the water. Suitable examples of such cosolvents are organic water miscible solvent, such as 1,4-dioxane, THF and acetone.
The full acids of the ligands of Formula (I) may be made from the corresponding half esters or full esters under known acidic hydrolysis conditions (see published application
WO 91/07911).
The present process is advantageous over those methods known in the art for the following reasons. The prior processes in which dialkyl phosphites under aqueous conditions are used give good results for acyclic amines, but less predictable results are obtained when macrocyclic ligands are employed. Furthermore, the macrocyclic ligand cyden is used, none of the desired ester is isolated. In contrast to the art, when the present process is used, the desired products of Formula (I) are obtained in all instances with yields in excess of 90%.
The invention will be further clarified by a consideration of the following examples, which are intended to be purely exemplary of the present invention. Some terms used in the following examples are defined as follows: g = gram(s); mg = milligrams; kg = kilogram(s); mL = milliliter(s); pL = microliter(s).
£ 9 0 0 / V 6 /d/dV
-4BAD ORIGINAL
AP. Ο Ο 5 4 3
General Materials and Methods.
All reagents were obtained from commercial suppliers and used as received without further purification. NMR spectra were recorded on a Bruker AC-250 MHz spectrometer equipped with a multi-nuclear quad probe CH, l3C3lP. and 19F) at 297’K unless otherwise indicated. Ή spectra in D2O were recorded by employing solvent suppression pulse sequence CPRESAT1, homo-nudear presaturation). 1H spectra are referenced to residual chloroform (in CDQj) at $7.26 or external dioxane fin DjO) at 53.55. iscand 3:P spectra reported are proton decoupled (broad band). Assignments of 13C (1H) chemical shifts were aided by DEPT (Distortionless Enhancement by Polarization Transfer) experiments. H} η 0 spectra are referenced to center peak of COCJ3 at $77.00 (in CDQ3) and external dioxane at 566.66 (in D2O). 51P{1H) spectra were referencedto external 85% HjPOzatSO-OO. Melting points were determined by capillary melt methods and were uncorrected. Semipreparative ion-exchange chromatographic separations were performed at low pressure (<600 psi) using a standard glass column fitted with hand-packed Q-Sepharose™ (anion exchange) or SP-15 Sepharose* (cation exchange) glass column, and wrthcn-line UVdeteaorat263nm foreluerrt monitoring. GC/MS spectra were performed on a Hewlett Packard 5890A Gas Chromatograph/ 5970 Mass Selective Detector.
The process to make the full ester derivatives of Formula (0 has been discussed before. Atypical procedure is as follows:
Example 1: Process for preparing 1,4,7,lO-tetraazacyciododecane-1A7,lO-methy1enedibijtyl phosphonate.
Cyden, tO g (58mmol), tributyl phosphite, 62 g (246 mmol) end paraformaldehyde, 7.4 g (246 mmol) were combined in 70 m L of THF and stirred at room temperature (the temperature was maintained below 40°O for 24 hrs. The homogeneous solution was then concentrated in vacuo to give a viscous oil (quantative yield) and characterized by: iHNMRiCDCh)
50.88 (m,24H), 133 (m, 16H), 1.59 (m, 16H), 2.80(s> 16H), 2.90 (d,8H), 4.00 (m, 16H);and »C£»H} NMR(CDOj)
5 13.51,18.65,32.49,32.57,49.04, 51.45,53.10,53.18; arid 51P NMR(CDCI3)
526.16 (s, 4P); and is illustrated by the formula σ>
ro (O
Cft έ;
•5BAD ORIGINAL
CE2PO3(C42g)2
IS <C«Eg)2O3FCH2
CH2P°3{C4Hg)2
Example 2: Process for preparing 1.4,7,10-tetrBazacyeladodeeane-i,4,7,l0-m ethyl enedi ethyl phosphonate.
When the procedure of Example 1 was repeated using triethyl phosphite in place of the tributyl phosphite, the title compound was obtained as viscous oil In greater than 98¾ yield and characterized by:
iHNMRfCDClg)
51.19 (m, 24H), 2.71 (s, 16H), 2.80 (d, 8H), 4.01 (m, 16H); and >3CCh} NMR (CDOj)
15.32,15.42,42.23,51.S7,53.18,53-28,61.34,61.45; and
31P NMRCCDCty
26.02 (s, 4P); and is illustrated by the formula r
( 25 (C2E5}2O3PCH2 ^Ce.2PO3 ( C2Hg ) 2 (C25s)203PCH^
ch2po3(c2hs)2 bad original $
Example 3: Preparation of N,N'-bis(methylenedimethylphosphonate)-2.11disza [3-31(2,6) pyd inaphane.
When the procedure of Example 1 was repeated using trimethyl phosphite in place of the tributyl phosphite and 2,11-diaza[33l(2,6)pydinophane in place of Cyden, the title compound was obtained as a very viscous oil in greater than 95% yield and further characterized by:
-61H NNlR(CDCls)
3 -39 (d, 4H), 3.88 (d, 12H), 4.08 (s. 8H), 6.84 (d. 4H), 7.13 (t, 2 H); and
13C{’H} NMRiCDCty
52.75(d), 54.88 (d), 65.21 (d), 122.71,135.69,157.14; and 5 3’PNMR(CDCh)
S 27_22; and is illustrated by the formula
AP.00543
example 4: Preparation of N.N'~bis(methyienediethyipho$phQnst<)*2,11 diaza[3J)(2.6)pydinophaneWhen the procedure of Example 1 was repeated using triethyl phosphite in place of the tributyl phosphite and 2,11-diaza[3 J](2,6)pydinophane in place of Cyden. the title
2q compound was obtained as a very viscous oil in greater than 95¾ yield and further characterized by:
1H NMRtCDa^
81.24 (t, 12H), 3-20 (d. 4H), 3-94 (s, 8h), 4.07 (q, 8H), 6.71 (d, 4H), 6.98 (t, 2H); and i3CfiH}NMR(CDa3) 2S 816.48.55.36 (d),61.75(d), 65.14 (d), 122.52,135.41,157.04; and 31P{1 H} NMR(CDOj)
24.60; and is illustrated by the formula
£ 9 0 0 / V 6 /d/dV
-7BAD ORIGINAL
Example 5: Preparation of N-(2-pyridylmethyl)-N',N,N'-tris(methylenediethylphosphonate)1,4,7,10-tetraazacyclodod ecane.
When the procedure of Example 1 was repeated using triethyl phosphite in place of the tributyl phosphite and N-(2-pyridylmethyl)-1,4,7,10-tetraazacydododecane in place of Cyden, the title compound was obtained as a very viscous oil in greater than 95% yield and further characterized by:
’HNMR(CDCI3) δ 1.25 -1.39 (m, 18H), 2.66 - 2.95 (m. 22H), 3.71 (s, 2H), 4.01 - 4.22 (m, 12H), 7.10 - 7.15 (m, 1H), 7.57 - 7.65 (m, 2H), 8.46 - 8.52 (m, 1H);
’3C{’H} NMR(CDCI3) δ 16.38, 16.46, 50.45, 50.67, 52.41, 53.19, 53.29, 53.48, 53.58,61.37, 61.47,61.52, 121.67, 123.28. 136.19, 148.61,159.90; and 3ip (l H} NMR(CDC13, 297°K)
26.21;
31P{1H) NMR(CDG3,217*K) δ 24.18 (1P), 24.32 (2P); and is illustrated by the formula
Example 6: Preparation of N-(2-pyridylmethyl)-N',N,N'-tris(methylenedipropylphosphonate)1,4,7,10-tetraazacyd od od ecane.
When the procedure of Example 1 was repeated using tripropyl phosphite in place of the tributyl phosphite and N-{2-pyridylmethyl)-1,4l7,10-tetraazacydododecane in place of Cyden, the title compound was obtained as a viscous oil in greater than 95% yield and further characterized by:
’HNMR(CDCI3) δ0.91 -1.00(m, 18H), 1.60-1.76(m. 12H), 2.67-2.99(m.22H),3.73(s,2H).3.94-4.08(m, 12H),
7.12 - 7.15 (m, 1H), 7.46 - 7.67 (m, 2H). 8.48 - 8.52 (m, 1H);
13C {’H) NMR(CDCI3) δ 9.93, 10.21,23.71, 23.80, 50.17, 50.44, 52.38, 53.09, 53.44, 61.44, 66.79,66.83, 121.61, 123.23, 136.14, 148.54,159.92; and 31P{1 H} NMR(CDC13) δ 26.20 (IP), 26.23 (2P); and is illustrated by the formula
-8BAD ORIGINAL
AP.00543
Example 7: Preparation of 3.6.9.15-tetraazabicvdo(9.3.11pentadeca-1( 15). 11.13-triene-3.6.9methylenediethylphosphonate.
θ When the procedure of Example 1 was repeated using triethyl phosphite in place of the tributyl phosphite and 3,6,9,15-tetraazabicycio[9.3.1]pentadeca-1(15),11,13-triene in place of Cyden, the title compound was obtained as a viscous oil in greater than 95% yield and further characterized by:
’HNMR(CDCI3) δ 1.23 (m, 18H), 2.77 (m, 12H), 3.04 (d, 6H), 4.13 (m, 12H), 7.17 (d, 2H), 7.60 (t. 1H); and 13CNMR(CDCI3) δ 16.43,50.03,50.31,50.43,50.77, 51.23,51.38,52.63,53.30.60.86,60.92,61.63,61.74,61.83, 61.93,62.32,76.46,76.97,77.18,77.48.122.50,137.10,157.18; and 31P NMR (CDCI3) δ 24.92 (s. 2P), 24.97 (s, 1P); and is illustrated by the formula
CH2-PO3 (C2H5) 2
AP/P/ 9 4 / 0 0 6 3 9
Example 8: Preparation of 3.6.9.15-tetraazabicvclof9.3.1 lpentadeca-1 (15),11,13-triene-3,6,930 methylenedi(n-propyl)phosphonate.
When the procedure of Example 1 was repeated using tripropyl phosphite in place of the tributyl phosphite and 3,6,9,15-tetraazabicydo(9.3.1]pentadeca-1(15),11,13-triene in place of Cyden, the title compound was obtained as a viscous oil in greater than 95% yield and further characterized by:
Ή NMR(CDCI3) δ0.88(m, 18H), 1.61 (m, 12H),2.72 (m, 12H),3.03(d,6H), 3.97(m, 12H), 7.13(d,2H),7.55(t, 1H); and
BAD ORIGINAL
-913C NMR(CDCI3) δ 9.96, 23.73, 49.84, 50.14, 50.26, 50.57, 51.11, 51.23, 52.43, 53.01, 60.78, 60.84, 67.27, 67.40, 122.48, 137.04, 157.16; and 3i P NMR (CDCI3) δ 24.98 (3P>; and is illustrated by the formula
ch2-po3(C3H7)2
Example 9: Preparation of 3,6,9,15-tetraazabicydo[9.3.1 lpentadeca-1 (15), 11,13-triene-3,6,9methylenedi(n-butyl)phosphonate.
When the procedure of Example 1 was repeated using tributyl phosphite in place of the tributyi phosphite and 3,6,9,15-tetraazabicydo[9.3.1]pentadeca-1(15),11,13-triene in place of Cyden, the title compound was obtained as a viscous oil in greater than 95% yield and further characterized by:
iHNMR(CDCI3)
0.84(m, 18H), 1.27(m, 12H), 1.58(m, 12H), 2.57(m, 12H),3.01 (d. 6H),3.99(m, 12H),7.12(d, 2H), 7.54 (t, 1H);and >3C NMR(CDCI3) δ 13.42,13.46, 18.50, 18.59, 32.16,32.43,49.88, 50.03, 50.16, 50.63, 51.11, 51.27, 52.48, 53.16,
60.71,60.78.65.38,65.48,65.58,122.46,136.96,157.14; and
31PNMR(CDCI3) δ 24.88 (2P), 24.93 (1 P); and is illustrated by the formula
ch2-po3(c4h9)2
-10BAD ORIGINAL &
AP.00543
The process to hydrolyze with base the full ester derivatives of Formula (I) to prepare the half esters of Formula (I) has been discussed before. Atypical procedure is as follows:
Example 10: Preparation of 1,4,7,10-tetracydododecane-1,4,7,105 tetramethylenebutylphosphonate, potassium salt.
The ester prepared in Example 1,3 g (3 mmol) was combined in an aqueous dioxane solution (100 mL water:25 mL dioxane), along with 3 g of KOH (48 mmol). The solution was stirred at reflux for 16 hrs. The one desired titled product was obtained as a solid (94% yield) as characterized by:
10 31PNMR(D2O)
621.87(s, 4P); and is illustrated by the formula
4K+
C4HgO3PCH^^ ,ch2po3c4h9 l I :4h9o3pch2 _I
CH2PO3C4Hg
62900/76 Zd/dV
For other ester derivatives where the alkyl ester is C1-C3 alkyl, hydrolysis proceeds without the dioxane cosolvent.
Example 11: Preparation of N,N'-bis(methylenephosphonicacid ethyl ester)-2,11diaza[3.3](2,6)pydinophane (BP2EP).
When the procedure of Example 10 was repeated using ester of Example 4, the title compound was obtained as a solid in greater than 95% yield and further characterized by: iHNMR(D2O) δ 1.10 (t, 6H), 2.97 (d, 4H), 3.81 (q, 4H), 3.84 (s, 8H), 6.73 (d, 4H), 7.09 (t, 2H); and
13C{1H} NMR(D2O) δ 18.98,58.76(d), 63.69(d), 66.53 (d). 126.35.140.09, 159.37; and
31P{1H} NMR(D2O) δ 20.65;; and is illustrated by the formula
-11BAD ORIGINAL
H(H5C2)O3P-H2C-N
N-CH2-PO3(C2H5)H
I ·,
I '
Example 12: Preparation of 3,6,9,15-tetraazabicyclo [9.3.1 Jpentadeca-1(15),11, 13-triene-3,6,9methylene(n-butyl)phosphonate tris(potassium salt) (PMBHE).
When the procedure of Example 10 was repeated using ester of Example 9, the title compound was obtained as a solid in greater than 95% yield and further characterized by: ’HNMR(D2O) δ 0.68 (m, 9H). 1.14(m,6H), 1.37 (m, 6H), 2.76 (d, 6H), 3.41 (m, 12H),3.73(m,6H),7.24(d,2H),
7.76 (t, 1H);and
13CNMR(D2O) δ 15.76,15.80.21.12,21.20,34.96,35.06.35.14, 52.08. 52.53,53.38,53.48,54.49,54.75,57.70,
57.76.61.86,67.65,67.75,67.98,68.08,12S.15,142.93, 152.25; and
31PNMR δ 9.73 (s, 2P), 21.00 (s, 1P); and is illustrated by the formula
ch2-po3c4h9
Example 13: Preparation of 3,6,9,15-tetraazabicyclo[9.3.1]pentadeca-1(15),11,13-triene-3,6,9methylene(n-propyl)phosphonate tris(potassium salt) (PM PHE).
When the procedure of Example 10 was repeated using ester of Example 8, the title compound was obtained as a solid in greater than 95% yield and further characterized by: 3’PNMR δ 20.49 (s, 3P); and is illustrated by the formula
-12BAD ORIGINAL
AP . Ο Ο 5 4 3
ch2-po3c3h7
Example 14: Preparation of 3,6,9,15-tetraazabicyclo[9.3.1]pentadeca-1 (15), 11,13-triene-3,6,9methyleneethylphosphonate tris(potassium salt) (PMEHE).
When the procedure of Example 10 was repeated using ester of Example 7, the title compound was obtained as a solid in greater than 95% yield and further characterized by: 13CNMR(D2O) 15 8 18.98,19.82, 51.78. 52.06, 53.08, 54.46, 54.68, 57.01, 58.22,60.24. 63.19, 63.25,63.36,63.49, 63.59,63.95,64.18,64.25,66.80,126.62,141.63,159.40; and 3iPNMR(D2O) δ 20.58 (s, 2P), 20.78 (s, 1P); and is illustrated by the formula
£ 9 0 0 7 * 6 /d/dV ch2-po3c2h5
Example 15: Preparation of N-{2-pyridylmethyl)-N'IN,N'-tris(methylenephosphonic acid ethyl ester)-1,4,7,10-tetraazacydododecane (PD3EP).
When the procedure of Example 10 was repeated using ester of Example 5, the title compound was obtained as a solid in greater than 95% yield and further characterized by: 1HNMR(D20.338* K) δ 1.41 -1.57 (m, 9H). 3.28 - 3.89 (m. 22H), 4.09 - 4.64(m, 8H), 8.22 - 8.26 (m, 2H). 8.70 - 8.75 (m. 1H), 9.00-9.12 (m, 1H); and 13C(’H) NMR (D20,338* K) δ 19.41,19.51, 52.58, 53.00, 52.31, 53.75, 53.82, 56.04, 59.53, 64.60,64.76, 129.86, 131.41,
147.31,149.06,154.34; and
-13BAD ORIGINAL
31P{ϊH} NMR(D2O.338 δ 9.64 (2P), 19.79 (1P);and is illustrated by the formula
Example 16: Preparation of N-(2-pyridylmethyl)-N',N,N'-tris(methy1enephosphonic acid 1θ propyl ester)-1,4,7,10-tetraazacydododecane(PD3PP).
When the procedure of Example 10 was repeated using ester of Example 6, the title compound was obtained as a solid in greater than 95% yield and further characterized by: Ή NMR (D20,353* K) δ 1.24 -1.36 (m, 9H), 1.95 - 2.04 (m, 6H), 3.03 - 3.29 (m, 22H), 4.10 - 4.25 (m, 8H), 7.74 - 7.92 (m,
2H). 8.23 - 8.29 (m, 1H), 8.87 - 8.96 (m. 1H); and ’3C{’H} NMR (O2O,353* K) δ 13.15, 27.20, 50.43. 53.89, 54.48, 54.98, 55.42, 64.33, 69.41, 126.38. 128.30,141.24,152.46, 161.45; and
31P{1H) NMR(D20,353*K) δ 21.61 (2P). 21.95 (1P);and is illustrated by the formula
H(H7C3)O3P-H2C --\l I
--Ν N
X
H(H7C3)O3P-H2C
The process to make the phosphonic add derivatives of Formula (I) has been discussed before. A typical procedure is as follows:
Example 17: Preparation of N,N -bis(methylenephosphonic aad)-2,11diaza[3.3](2,6)pydinophane (BP2P).
A cone. HCl solution (37%,4mL) of N.N -bis(methylenedimethylphosphonate)2,11 -diaza[3.3](2,6)pydinophane, prepared in Example 3, (255 mg, 0.53 mmol) was heated at reflux for 2.5 hr. After cooling, the solution was evaporated to dryness, followed by co35 evaporation with fresh deionized water (3 X 2 mL) to eliminate excess HCl. The final product was isolated as a hygroscopic brown solid upon freeze-drying of the concentrated aqueous solution; and characterized by:
-14BAD ORIGINAL $
AP.00543
Ή NMR(D2O)
3.55 (d, 4H), 4.46 (br s, 8H), 6.90 (d, 4H), 7.37 (t, 2H); and 13C{’H} NMR(D2O) δ57.80(d),63.74(d), 127.02,144.18, 152.96; and 5 3'P{1H}NMR(D2O) δ 11.71; and is illustrated by the formula h2o3p-h2c-n
4-CH2-PO3H2
Example 18: Preparation of Ethylenediaminetetramethylenephosphonic acid (EDTMP).
To a cooled (0*0 THF solution (20 mL) of triethyl phosphite (23 g, 140 mmol) and paraformaldehyde (4.2 g, 140 mmol) was added ethylenediamine (2 g, 33.3 mmol) with stirring. After complete addition the solution was gradually warmed to room temperature and stirring continued for 12 hrs. The solution was then concentrated in vacuo to give the tetraethyl phosphonate ester as a viscous oil.
The tetraethyl phosphonate ester (2 g) was heated to 100’C for 6 hrs. in 12M HCI (50 ml). The solution was then cooled in an ice bath to give EDTMP as a white crystalline solid.
Other embodiments of the invention will be apparent to those skilled in the art
from a consideration of this specification or practice of the invention disclosed herein. It is 25 intended that the specification and examples be considered as exemplary only, with the true scope and spirit of the invention being indicated by the following daims.
AP/P/ 9 4 / 0 0 6 3 9
Claims (15)
- CLAIMS:1. A process for preparing azamacrocydic or acyclic aminophosphonate ester derivatives which possess at least one secondary or primary nitrogen atom substituted with at least one moiety of the formula5 -CH2PO3RR1 (I) wherein:R is H or C1-C5 alkyl; with the proviso that each R is the same group;R' is C1-C5 alkyl, H, Naor K; with the proviso that each R and R1 is the same group when C1-C5 alkyl;IQ which comprises reacting the corresponding unsubstituted amine compound with a trialkyl phosphite and paraformaldehyde to provide the derivatives of Formula (I) wherein all R and R1 equal C1-C5 alkyl; and (a) optionally followed by aqueous base hydrolysis to provide the derivatives of Formula (I) wherein R is C,-C5 alkyl and R1 is H, Na or K; and/or15 (b) optionally followed by acid hydrolysis to provide the derivatives of Formula (I) wherein all R and R1 equal H.
- 2. The process of Claim 1 wherein the derivative product of Formula (I) has all R and R1 equal C1-C5 alkyl.
- 3. The process of Claim 2 for preparing 1,4,7,10-tetraazacydododecane-1,4,7,1020 methylenedibutyl phosphonate which comprises reacting cyclen with tributyl phosphite and paraformaldehyde in THF.
- 4. The process of Claim 2 for preparing 1,4,7,10-tetraazacyclododecane-1,4,7,10methylenediethyl phosphonate which comprises reacting cyclen with triethyl phosphite and paraformaldehyde in THF.25 5. .The process of Claim 2 for preparing N,N'-bis(methylenedimethylphosphonate)-2,11-diaza[3.3](2,6)pydinophane which comprises reacting 2,11diaza[3.3](2,6)pydinophane with trimethyl phosphite and paraformaldehyde in THF6. The process of Claim 2 for preparing N,N'-bis(methylenediethylphosphonate)2,11-diaza(3.3](2,6)pydinophane which comprises reacting 2,11-diaza[3 3](2,6)pydinophane30 with triethyl phosphite and paraformaldehyde in THF.7. The process of Claim 2 for preparing N-(2-pyridylmethyl)-N',N,N'-tris(methylenediethylphosphonate)-1,4,7,10-tetraazacydododecane which comprises reacting N-(2-pyridylmethyl)-1,4,7,10-tetraazacydododecane with triethyl phosphite and paraformaldehyde in THF.35 8. The process of Claim 2 for preparing N-(2-pyridylmethyl)-N',N,N'-tris(methylenedipropylphosphonate)-1,4,7,10-tetraazacydododecane which comprises reacting N-(2-pyridylmethyl)-1,4,7,10-tetraazacyclododecane with tri propyl phosphite andAP/P/ 9 4 / 0 0 6 3 941,184-8AP . 0 0 5 4 39. The process of Claim 2 for preparing 3,6,9,15-tetraazabicydo[9.3.1 Jpentadeca1(15),11,13-triene-3,6,9-methylenediethylphosphonate which comprises reacting 3,6,9,15tetraazabicyclo[9 3.1]pentadeca-1 (15),11,13-triene with triethyl phosphite and paraformaldehyde in THF.
- 5 10. The process of Claim 2 for preparing 3,6,9,15tetraazabicyclo[9.3.1]pentadeca-1( 15),11,13-triene-3,6,9-methylenedi(n-propyl)phosphonate which comprises reacting 3,6,9,15-tetraazabicydo(9.3.1]pentadeca-1(15),11,13-triene with tripropyl phosphite and paraformaldehyde in THF.11. The process of Claim 2 for preparing 3,6,9,1510 tetraazabicyclo[9.3.1 Jpentadeca-1( 15), 11,13-triene-3,6,9-methylenedi(n-butyl)phosphonate which comprises reacting 3,6,9,15-tetraazabicyclo(9.3.1 Jpentadeca-1 (15), 11,13-triene with tri butyl phosphite and paraformaldehyde in THF.ί 12. The process of Claim 1 wherein the derivative product of Formula (I) has all R ( equal H, Na or K and all R1 equal C1-C5 alkyl.,5 13. The processof Claim 12 forpreparing 1,4,7,10-tetracyclododecane-1,4,7,10tetramethylenebutylphosphonate, tetrapotassium salt, which comprises reacting cyclen with tributyl phosphite and paraformaldehyde in THF to form 1,4,7,10-tetraazacydododecane1,4,7,10-methylenedibutyl phosphonate, followed by separating the formed intermediate, and then basic hydrolysis with KOH in a cosolvent of water and dioxane to form the desired20 product.14. The processof Claim 12 forpreparing N,N’-bis(methylenephosphonic acid ethyl ester)-2,11-diaza[3.3J(2,6)pydinophane which comprises reacting 2,11diaza[3.3](2,6)pydinophane with triethyl phosphite and paraformaldehyde in THF to form N,N bis(methylenediethylphosphonate)-2,11-diaza[3.3](2,6)pydinophane, followed by separating25 the formed intermediate, and then basic hydrolysis with KOH in water to form the desired , product.15. The processof Claim 12 forpreparing 3,6,9,15-tetraazabicydo[9.3.1 Jpentadeca-1 (15), 11,13-triene-3,6,9-methylene(n-butyl)phosphonate tris(potassium salt) which comprises reacting 3,6,9,15-tetraazabicyclo(9.3.1 Jpentadeca30 1 (15), 11,13-triene with tributyl phosphite and paraformaldehyde in THF to form 3,6,9,15tetraazabicyclo[9.3.1 Jpentadeca-1 (15), 11,13-triene-3,6,9-methylenedi(n-butyl)phosphonate, followed by separating the formed intermediate, and then basic hydrolysis with KOH in a cosolvent of water and dioxane to form the desired product.16. The process of Claim 12 forpreparing 3,6,9,15-tetraaza35 bicydo[9.3.1 Jpentadeca-1(15),11,13-triene-3,6,9-methylene(n-propyl)phosphonate tris(potassium salt) which comprises reacting 3,6,9,15-tetraazabicyclo[9.3.1 Jpentadeca1(15),11,13-triene with tri propyl phosphite and paraformaldehyde in THF to form 3,6,9,15tetraazabicydo[9.3 1 Jpen-adeca-1 (15), 11,13-triene-3,6,9-methylenedi(n-propyl)phosphonate,AP/P/ 9 4 / 0 0 6 3 941,184-»' followed by separating the formed intermediate, and then basic hydrolysis with KOH in water to form the desired product17. The process of Claim 12forpreparing3,6,9,15-tetraazabicydo[9.3.1]pentadeca-1(l 5),11,13-triene-3,6,9-methyleneethylphosphonate tris(potassium5 salt) which comprises reacting 3,6,9,15-tetraazabicydo[9.3 1 Jpentadeca-1(15),11,13-triene with triethyl phosphite and paraformaldehyde in THF to form 3,6,9,15tetraazabicyclo[9.3.1]pentadeca-1(1 5),11,13-triene-3,6,9-methylenediethylphosphonate, followed by separating the formed intermediate, and then basic hydrolysis with KOH in water to form the desired product.
- 10 18. The process of Claim 12 for preparing N-(2-pyridylmethyl)-N',N,N'tris(methylenephosphonic acid ethyl ester)-1,4,7,10-tetraazacydododecane which comprises reacting N-(2-pyridylmethyl)-1,4,7,10-tetraazacydododecane with triethyl phosphite and paraformaldehyde in THF to form N-(2-pyridylmethyl)-N',N,N'-tris(methylenediethylphosphonate)-1,4,7,l0-tetraazacydododecane, followed by separating the formed
- 15 intermediate, and then basic hydrolysis with KOH in water to form the desired product.
- 19. The process of Claim 12 for preparing N-(2-pyridylmethyl)-N',N,N‘tris(methylenephosphonic acid propyl ester)-1,4,7,10-tetraazacydododecane which comprises reacting N-(2-pyridylmethyl)-1,4,7,10-tetraazacydododecane with tripropyl phosphite and paraformaldehyde in THF to form N-(2-pyridylmethyl)-N',N,N'-tris(methylenedipropyl20 phosphonate)-1,4,7,10-tetraazacydododecane, followed by separating the formed intermediate, and then basic hydrolysis with KOH in water to form the desired product.
- 20. The process of Claim 1 wherein the derivative product of Formula (I) has all R and R1 equal H, NaorK.
- 21. The process of Claim 20 for preparing N,N’-bis(methylenephosphonic acid)25 2,11-diaza[3.3)(2,6)pydinophane which comprises reacting 2,11-diaza[3.3)(2,6)pydinophane with trimethyl phosphite and paraformaldehyde in THF to form N,N bis(methylenedimethylphosphonate)-2,11-diaza(3.3J(2,6)pydinophane, which intermediate was add hydrolyzed with heated HCI, and then the desired product separated.
- 22. The process of Claim 1 wherein the trialkyl phosphite is a tri(Ci-C4 alkyl)3θ phosphite.
- 23. The process of Claim 1, part (a), wherein the aqueous base is an alkali metal hydroxide.
- 24. The process of Claim 1, part (a), wherein the R or R1 group is C3-C5 alkyl and an organic water miscible cosolvent is present.35 25. The process of Claim 1 wherein the derivative of Formula (I) is an azamacrocydic ligand where R and R1 are both the same Ci -C5 alkyl, and the temperature is maintained below 40’C during the first hour of the reaction.AP/P/ 9 4 / 0 0 6 3 9BAD ORIGINAL41 184-rAP. Ο Ο 5 4 326. The process of Claim 1 wherein the derivative of Formula (I) is an azamacrocydic ligand where R and R’ are both the same C1-C5 alkyl, and a non-aqueous liquid is present.27. The process of Claim 26 wherein the liquid is an aprotic polar solvent or5 alcohol.28. The process of Claim 27 wherein the solvent is tetrahydrofuran.29. The process of Claim 1 wherein the derivative of Formula (I) is an acyclic amine where R and R> are both the same C1-C5 alkyl, and the temperature is maintained below 40°C during the first hour of the reaction.10 30. The process of Claim 29 wherein a trialkyl phosphite and paraformaldehyde are combined and initially cooled, followed by the controlled addition of the acyclic amine, and the temperature is maintained by using an ice bath.31. The process of Claim 29 wherein the acyclic amine isethylenediamine, diethylenetriamine, ortriethylenetetraamine.15 32. The process of Claim 31 wherein base hydrolysis provides the mono-alkyl phosphonates.33. The process of Claim 32 wherein acid hydrolysis provides the corresponding phosphonic acids derivatives which are ethylenediaminetetramethylenephosphonic acid, diethylenetriaminepentamethylenephosphonic acid, or triethylenetetraamine20 hexamethylenephosphonic acid.34. The process of Claim 1 wherein the azamacrocydic or acyclic aminophosphonate derivatives are represented by the formulaA-(N-CH2CH2-N)q-Z (II) wherein:
- 25 q is an integer from 1 to 5 inclusive;A may be 0, 1 or 2 moieties of Formula (I) as claimed in Claim 1 or hydrogen;Z may be 0,1 or 2 moieties of Formula (I) as claimed in Claim 1 or hydrogen; with the proviso that at least one A or Z moiety of Formula (I) as claimed in Claim 1 is present; and
- 30 A and Z may be joined to form a cyclic compound.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/065,963 US5714604A (en) | 1993-05-06 | 1993-05-06 | Process for the preparation of azamacrocyclic or acyclic aminophosphonate ester derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AP9400639A0 AP9400639A0 (en) | 1994-07-31 |
| AP543A true AP543A (en) | 1996-10-09 |
Family
ID=22066341
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| APAP/P/1994/000639A AP543A (en) | 1993-05-06 | 1994-05-06 | Process for the preparation of azamacrocyclic or acyclic aminophosphonate ester derivatives. |
Country Status (35)
| Country | Link |
|---|---|
| US (1) | US5714604A (en) |
| EP (1) | EP0698029B1 (en) |
| JP (1) | JP3556669B2 (en) |
| KR (1) | KR100311560B1 (en) |
| CN (1) | CN1042537C (en) |
| AP (1) | AP543A (en) |
| AT (1) | ATE172978T1 (en) |
| AU (1) | AU682190B2 (en) |
| BG (1) | BG62775B1 (en) |
| CA (1) | CA2162170C (en) |
| CO (1) | CO4230080A1 (en) |
| CZ (1) | CZ290993B6 (en) |
| DE (1) | DE69414382T2 (en) |
| DK (1) | DK0698029T3 (en) |
| DZ (1) | DZ1777A1 (en) |
| EE (1) | EE03159B1 (en) |
| EG (1) | EG20296A (en) |
| ES (1) | ES2123137T3 (en) |
| FI (1) | FI115632B (en) |
| HK (1) | HK1014537A1 (en) |
| HU (1) | HU223769B1 (en) |
| IL (1) | IL109561A (en) |
| IS (1) | IS1735B (en) |
| LT (1) | LT3713B (en) |
| LV (1) | LV10867B (en) |
| MA (1) | MA23186A1 (en) |
| NO (1) | NO304742B1 (en) |
| PL (1) | PL180756B1 (en) |
| RO (1) | RO115883B1 (en) |
| RU (1) | RU2135507C1 (en) |
| TN (1) | TNSN94040A1 (en) |
| TW (1) | TW273549B (en) |
| UA (1) | UA44704C2 (en) |
| WO (1) | WO1994026753A1 (en) |
| ZA (1) | ZA943158B (en) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6207826B1 (en) | 1995-03-27 | 2001-03-27 | Isis Pharmaceuticals, Inc. | Macrocyclic compounds having nitrogen-containing linkages |
| US6107482A (en) | 1995-03-27 | 2000-08-22 | Isis Pharmaceuticals, Inc. | Nitrogenous macrocyclic compounds |
| EP1191948A2 (en) * | 1999-06-11 | 2002-04-03 | Neorx Corporation | High dose radionuclide complexes for bone marrow suppression |
| US7094885B2 (en) * | 1999-07-11 | 2006-08-22 | Neorx Corporation | Skeletal-targeted radiation to treat bone-associated pathologies |
| US6794371B1 (en) * | 1999-10-18 | 2004-09-21 | The Dow Chemical Company | Aminoalkylenephosphonates for treatment of bone disorders |
| JP2003512331A (en) * | 1999-10-18 | 2003-04-02 | ザ ダウ ケミカル カンパニー | Aminoalkylene phosphonate for treatment of bone disorders |
| US6565828B2 (en) * | 2000-04-07 | 2003-05-20 | Bristol-Myers Squibb Company | Macrocyclic chelants for metallopharmaceuticals |
| EP1390081A2 (en) * | 2001-01-08 | 2004-02-25 | Neorx Corporation | Therapeutic and diagnostic compounds, compositions, and methods |
| JP2005507005A (en) * | 2001-10-22 | 2005-03-10 | テキサス テック ユニバーシティー | Tissue-specific fluorescent chelate |
| US20030133872A1 (en) * | 2001-10-22 | 2003-07-17 | Kiefer Garry E. | Radiopharmaceutical agent for the treatment of early stage cancer |
| US7045116B2 (en) | 2001-12-13 | 2006-05-16 | Dow Global Technologies Inc. | Treatment of osteomyelitis with radiopharmaceuticals |
| US20050112066A1 (en) * | 2003-11-26 | 2005-05-26 | Concat Lp, A California Limited Partnership | Complexes of cyclic polyaza chelators with cations of alkaline earth metals for enhanced biological activity |
| EP1778699A4 (en) * | 2004-08-10 | 2009-02-25 | Dow Global Technologies Inc | Targeting chelants and chelates |
| CN112442069A (en) * | 2019-08-28 | 2021-03-05 | 广东广山新材料股份有限公司 | Phosphorus-containing flame retardant with amido, preparation method and application thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0382582A1 (en) * | 1989-02-10 | 1990-08-16 | Celltech Therapeutics Limited | Tetra-aza macrocyles and processes for their preparation |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5362476A (en) * | 1984-10-18 | 1994-11-08 | Board Of Regents, The University Of Texas System | Alkyl phosphonate polyazamacrocyclic cheates for MRI |
| GB8817185D0 (en) * | 1988-07-19 | 1988-08-24 | Interox Chemicals Ltd | Organic polyphosphonates |
| US5342936A (en) * | 1989-02-10 | 1994-08-30 | David Parker | Tetra-aza macrocycles and processes for their preparation |
| WO1991007911A1 (en) * | 1989-11-27 | 1991-06-13 | Concat Ltd. | Mri image enhancement of bone and related tissue using complexes of paramagnetic cations and polyphosphonate ligands |
| US5236695A (en) * | 1989-11-27 | 1993-08-17 | Concat, Ltd. | MRI image enhancement of bone and related tissue using complexes of paramagnetic cations and polyphosphonate ligands |
| US5385893A (en) * | 1993-05-06 | 1995-01-31 | The Dow Chemical Company | Tricyclopolyazamacrocyclophosphonic acids, complexes and derivatives thereof, for use as contrast agents |
| US5606053A (en) * | 1995-05-02 | 1997-02-25 | Johnson Matthey Plc | Process for preparing 1,1'-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane |
-
1993
- 1993-05-06 US US08/065,963 patent/US5714604A/en not_active Expired - Lifetime
-
1994
- 1994-05-04 EP EP94917333A patent/EP0698029B1/en not_active Expired - Lifetime
- 1994-05-04 AT AT94917333T patent/ATE172978T1/en not_active IP Right Cessation
- 1994-05-04 WO PCT/US1994/005134 patent/WO1994026753A1/en active IP Right Grant
- 1994-05-04 PL PL94311651A patent/PL180756B1/en not_active IP Right Cessation
- 1994-05-04 HU HU9503175A patent/HU223769B1/en not_active IP Right Cessation
- 1994-05-04 DK DK94917333T patent/DK0698029T3/en active
- 1994-05-04 DE DE69414382T patent/DE69414382T2/en not_active Expired - Lifetime
- 1994-05-04 KR KR1019950704944A patent/KR100311560B1/en not_active IP Right Cessation
- 1994-05-04 DZ DZ940043A patent/DZ1777A1/en active
- 1994-05-04 CA CA002162170A patent/CA2162170C/en not_active Expired - Fee Related
- 1994-05-04 JP JP52562094A patent/JP3556669B2/en not_active Expired - Fee Related
- 1994-05-04 RO RO95-01927A patent/RO115883B1/en unknown
- 1994-05-04 CZ CZ19952890A patent/CZ290993B6/en not_active IP Right Cessation
- 1994-05-04 CN CN94192530A patent/CN1042537C/en not_active Expired - Fee Related
- 1994-05-04 AU AU69086/94A patent/AU682190B2/en not_active Ceased
- 1994-05-04 ES ES94917333T patent/ES2123137T3/en not_active Expired - Lifetime
- 1994-05-04 UA UA95114920A patent/UA44704C2/en unknown
- 1994-05-05 IL IL10956194A patent/IL109561A/en not_active IP Right Cessation
- 1994-05-05 RU RU95122389A patent/RU2135507C1/en not_active IP Right Cessation
- 1994-05-05 MA MA23494A patent/MA23186A1/en unknown
- 1994-05-05 IS IS4158A patent/IS1735B/en unknown
- 1994-05-06 CO CO94018967A patent/CO4230080A1/en unknown
- 1994-05-06 ZA ZA943158A patent/ZA943158B/en unknown
- 1994-05-06 AP APAP/P/1994/000639A patent/AP543A/en active
- 1994-05-06 LT LTIP1925A patent/LT3713B/en not_active IP Right Cessation
- 1994-05-06 LV LVP-94-99A patent/LV10867B/en unknown
- 1994-05-06 TN TNTNSN94040A patent/TNSN94040A1/en unknown
- 1994-05-07 EG EG26094A patent/EG20296A/en active
- 1994-05-18 TW TW083104130A patent/TW273549B/zh not_active IP Right Cessation
- 1994-07-14 EE EE9400087A patent/EE03159B1/en not_active IP Right Cessation
-
1995
- 1995-11-03 FI FI955281A patent/FI115632B/en not_active IP Right Cessation
- 1995-11-06 NO NO953800A patent/NO304742B1/en not_active IP Right Cessation
- 1995-12-05 BG BG100193A patent/BG62775B1/en unknown
-
1998
- 1998-12-28 HK HK98115751A patent/HK1014537A1/en not_active IP Right Cessation
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0382582A1 (en) * | 1989-02-10 | 1990-08-16 | Celltech Therapeutics Limited | Tetra-aza macrocyles and processes for their preparation |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AP543A (en) | Process for the preparation of azamacrocyclic or acyclic aminophosphonate ester derivatives. | |
| Moedritzer et al. | The direct synthesis of α-aminomethylphosphonic acids. Mannich-type reactions with orthophosphorous acid | |
| JP2563954B2 (en) | 1-Hydroxy-3- (N-methyl-N-propylamino) propane-1,1-diphosphonic acid and therapeutic agent for calcium metabolism disorder containing this compound | |
| AU728902B2 (en) | Process for synthesizing phosphodiesters | |
| CZ287453B6 (en) | Derivatives of bisphosphonic acid, process of their preparation and pharmaceutical preparation containing thereof | |
| RU95122389A (en) | METHOD FOR PRODUCING AZAMACROCYCLIC OR ACYCLIC AMINOPHOSPHONATE DERIVATIVES | |
| Urbanovský et al. | Selective and clean synthesis of aminoalkyl-H-phosphinic acids from hypophosphorous acid by phospha-Mannich reaction | |
| FI83421B (en) | FOERFARANDE FOER FRAMSTAELLNING AV FARMAKOLOGISKT ANVAENDBARA METYLENBISFOSFONSYRADERIVAT. | |
| Gallagher et al. | MONO-AND DIALKYLATION OF ISOPROPYL PHOSPHINATE-A SIMPLE PREPARATION OF ALKYLPHOSPHINATE ESTERS1 | |
| NZ231515A (en) | Preparation of n-acylaminomethylphosphonic acid derivatives | |
| JP3206602B2 (en) | Method for producing derivatives of ascorbic acid | |
| Failla et al. | SYNTHESIS AND CHARACTERIZATION OF AMINOPYRIDIN-2-YL-METHYL-PHOSPHONIC ACIDS | |
| Varga | Synthesis of bis (aminomethyl)-phosphinic acids via a Mannich reaction | |
| BG62140B1 (en) | Method for the preparration of aminomethanephosphonic acid | |
| Juribasic et al. | Unexpected course of Kabachnik-Fields reaction in the microwave synthesis of quinoline-based α-aminophosphonates | |
| Iwamoto et al. | Preparation of alkyl dihydrogenphosphates with monomeric metaphosphate anion generated by photochemical CP bond cleavage of p-nitrobenzylphosphonic acid. | |
| Ries et al. | Synthesis of alkylphosphonates, a new class of antineoplastic agents | |
| Even et al. | Synthesis of new ligands derived from polyphosphonates partial esters | |
| PL217204B1 (en) | Process for the preparation of bis(dialkylaminemethyl)phospinic acids | |
| Turhanen | Design and synthesis of novel (1-hydroxyethylidene)-1, 1-bisphosphonic acid derivatives as possible prodrugs of etidronate | |
| JP2002506871A (en) | Use of aminophosphonates as pH markers in 31P NMR |